The management of well-differentiated gastroenteropancreatic neuroendocrine tumours in a tertiary centre – The contribution of radionuclide therapy

#4451

Introduction: Neuroendocrine tumours represent a heterogenous group of tumours with different locations, whose management is necessary to identify specific parameters that determine the choice of optimal treatment.

Aim(s): Evaluation of specific biochemical parameters and RECIST 1.1 criteria in patients with G1 and G2 gastroenteropancreatic NETs before and 1 year after combined therapy.

Materials and methods: 18 patients with G1 and G2 GEP-NETs registered at National Institute of Endocrinology, Bucharest, Romania, divided in 2 equal groups, with and without radionuclide therapy Lu177.

Conference:

Presenting Author: Oana Stefania S

Authors: Oana Stefania S, Corin B, Victoria V, Sofia L,

Keywords: GEP-NET, well-differentiated, PRRT, Cromogranine A, Serotonin, RECIST 1.1,